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Abstract
Objectives and background: Complex peripheral arterial disease (PAD) and critical
limb ischemia (CLI) are associated with high morbidity and mortality. Endovascular
techniques have become prevalent in treatment of advanced PAD and CLI, and use
of techniques such as tibiopedal minimally invasive revascularization (TAMI), have
been proven safe in small, single-center series. However, its use has not been sys-
tematically compared to traditional approaches.
Methods and results: This is a retrospective, multicenter analysis which enrolled
744 patients with advanced PAD and CLI who underwent 1,195 endovascular inter-
ventions between January 2013 and April 2018. Data was analyzed based on access
used for revascularization: 840 performed via femoral access, 254 via dual access,
and 101 via TAMI. The dual access group had the highest median Rutherford Class
and lowest number of patent tibial vessels. Median fluoroscopy time, procedure time,
hospital stay, and contrast volume were significantly lower in the TAMI access group
when compared to both femoral/dual access groups. There was also a significant dif-
ference between all groups regarding location of target lesions: Femoropopliteal
lesions were most commonly treated via femoral access; infrapopliteal lesions, via
TAMI, and multilevel lesions via dual access.
Conclusions: Stand-alone TAMI or tibial access as an integral part of a dual access
treatment strategy, is safe and efficacious in the treatment of patients with advanced
PAD and CLI who have infrapopliteal lesions. Larger prospective and randomized
studies may be useful to further validate this approach.
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1 | INTRODUCTION
Peripheral artery disease (PAD) is a worldwide epidemic, which impacts
one in 10 patients over the age of 70 years.1 Critical limb ischemia (CLI)
represents the most advanced stage of PAD, and is defined as the pres-
ence of rest pain and/or ulceration of the feet. Patients with CLI have a
significant risk of amputation due to disruption of the distal microcircu-
lation and its ability to provide nutrient-rich arterial blood flow to the
lower extremity end-organ. Patients with PAD and CLI tend to suffer
from significant comorbidities including cerebrovascular and coronary
artery disease, diabetes, chronic renal failure, hypertension, dys-
lipidemia, and tobacco abuse.2–4 These comorbidities not only worsen
the prognosis of these patients but may also limit the patient's ability to
undergo surgical revascularization.
As such, endovascular revascularization techniques have continued
to increasingly become the most common therapeutic choice when
compared to open surgical approaches.5 This trend is in part a reflection
of the predominant frailty characteristic of CLI patients (which makes
them less suitable candidates for surgery), and a consequence of the
increased availability of endovascular technologies coupled with a rapid
adoption and evolving mastery of these new devices and techniques.
However, even endovascular therapy (EVT) may prove challenging to
perform on a number of patients. Limitations include inadequate arte-
rial access sites due to severely diseased common femoral artery con-
duits, inability of the patients to lay flat, severe morbid obesity, infected
groins, and/or increased risk for contrast-induced nephropathy in
patients with baseline chronic kidney disease. The Tibiopedal Arterial
Minimally Invasive (TAMI) retrograde revascularization technique is an
innovative modality for tibiopedal access and treatment,6 that seeks to
circumvent some of these limitations.
Since its introduction in 2013, the TAMI technique has been used
to provide treatment for patients lacking the ability to be treated from
an antegrade femoral and/or contralateral retrograde femoral
approach (due to the aforementioned reasons). Thus far, no analysis
has been done comparing the use of the TAMI technique with the
more traditional endovascular access approaches, nor are we aware of
any outcomes data. This study seeks to examine and compare the use
of this strategy and its outcomes versus those obtained in patients
who underwent revascularization via the traditional femoral access
approach or the dual access approach (antegrade ipsilateral femoral or




This is a retrospective analysis of prospectively collected data, as part
of a multicenter study of consecutive PAD and CLI subjects who
underwent lower extremity endovascular revascularization in five cen-
ters in the United States between January 2013 and April 2018, as
part of the Peripheral RegIstry of Endovascular Clinical OutcoMEs
(PRIME Registry).7 Institutional Review Board approval was obtained
at each institution and subject consents were attained prior to any
procedures or data collection. Eligible subjects were adults ≥ 18 years
with symptomatic PAD (Rutherford class 3) and CLI (Rutherford class
4–6) undergoing EVT of a lower extremity.
2.2 | Procedure
Endovascular revascularization was attempted on all study subjects.
Access type was determined by the treating physician and included
one of the following: ipsilateral common femoral or superficial femo-
ral antegrade access; contralateral common femoral retrograde
access; dual access (common femoral antegrade/retrograde access +
tibial pedal access), or TAMI access (retrograde tibial-pedal access
alone with the intention to carry the intervention from this access
site). Revascularization methods were also determined by the
treating physician and included one or a combination of the follow-
ing: atherectomy, percutaneous transluminal angioplasty (PTA),
drug-coated balloon angioplasty (DCB), bare-metal stent (BMS) or
drug-eluting stent (DES) placement.
2.3 | Outcomes and definitions
Postrevascularization angiography was performed to assess treatment
success, which was defined as ≤30% final residual stenosis.
Complications were defined as the occurrence of any of the fol-
lowing in the treated vessel and/or at the access site: arterio-venous
fistula, thrombus, aneurysm, pseudoaneurysm, hematoma (defined as
subcutaneous blood collection with induration measuring more than
3 cm in diameter), infection, retroperitoneal bleed, compartment syn-
drome, postprocedural need for blood transfusion, unplanned above
the ankle amputation, embolization, dissection, and persistent vaso-
spasm. Perforations were classified as mild, moderate and severe. Mild
perforations were defined as delayed extravasation after contrast
injection, with uninterrupted blood flow beyond the extravasation
site, which resolves with prolonged balloon inflation. Moderate was
defined as immediate contrast extravasation, with uninterrupted
blood flow beyond the extravasation site, which resolves with pro-
longed balloon inflation. Severe was defined as immediate contrast
extravasation, with interrupted blood flow beyond the extravasation
site, which requires treatment with covered stents or coils. Vessel rup-
ture was defined as immediate contrast extravasation which requires
open surgical intervention for repair.
Complication-free result was defined as no complications
between the end of the procedure and the time of patient discharge.
2.4 | Data analysis
Categorical variables were reported as counts and percentages and
continuous variables were reported as median and interquartile range
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(IQR). Three groups were analyzed: Femoral access, Dual access, and
TAMI access. Two-sided omnibus p-values for group differences, were
derived from Fisher's exact test for categorical variables and Kruskal–
Wallis analysis of variance for continuous variables. When group dif-
ferences were identified by an omnibus p-value less than .05,
Bonferroni post hoc tests were performed among all pairwise compar-
isons. Statistical significance was defined as p < .01. Data were ana-
lyzed with SAS v9.4 (SAS Institute, Cary, NC).
3 | RESULTS
A total of 744 subjects clinically diagnosed with PAD and CLI under-
went 1,195 endovascular lower extremity revascularization proce-
dures. Subject data was analyzed based on the type of access method
used for revascularization: 840 interventions were carried via a femo-
ral (ipsilateral antegrade or contralateral retrograde) access, 254 inter-
ventions were carried via dual access (femoral + tibial-pedal), and
TABLE 1 Comparison of patient characteristics by access type at index procedure
Characteristic
Access type Significancea
TAMI Femoral Dual access Omnibus Bonferroni
(46 patients) (546 patients) (152 patients) p-value Post hoc
Demographics
Age, y 65.3 (59.4–78.3) 69.8 (61.9–77.4) 72.5 (64.2–79.1) .03 b
Male gender 67.4% (31/46) 61.4% (335/546) 73.0% (111/152) .03 c
Race .76
White 91.3% (42/46) 91.4% (499/546) 93.4% (142/152)
Black 8.7% (4/46) 6.6% (36/546) 5.9% (9/152)
Other 0.0% (0/460) 2.0% (11/546) 0.7% (1/152)
Body mass index, kg/m2 31.4 (25.6–35.1) 28.4 (25.0–32.7) 28.6 (25.8–32.7) .10
Insurance .28
Medicare 71.7% (33/46) 73.3% (400/546) 79.6% (121/152)
Private 15.2% (7/46) 20.0% (109/546) 14.5% (22/152)
Medicaid 13.0% (6/46) 5.9% (32/546) 5.9% (9/152)
Self-pay/no insurance 0.0% (0/46) 0.9% (5/546) 0.0% (0/152)
Medical history
Hypertension 95.7% (44/46) 85.7% (468/546) 88.2% (134/152) .14
Peripheral artery disease 93.5% (43/46) 92.7% (506/546) 92.8% (141/152) >.99
Dyslipidemia 91.3% (42/46) 83.2% (454/546) 90.8% (138/152) .03 b
Diabetes mellitus 67.4% (31/46) 53.3% (291/546) 57.9% (88/152) .14
Smoking history 65.2% (30/46) 81.0% (442/546) 73.7% (112/152) .01 b
Coronary artery disease 54.3% (25/46) 54.2% (296/546) 59.2% (90/152) .55
Prior endovascular procedure 37.0% (17/46) 40.3% (220/546) 44.7% (68/152) .53
Prior coronary intervention 28.3% (13/46) 30.0% (164/546) 30.9% (47/152) .95
Myocardial infarction 26.1% (12/46) 22.3% (122/546) 19.1% (29/152) .53
Coronary artery bypass graft 21.7% (10/46) 21.1% (115/546) 31.1% (47/151) .04 c
COPD 17.4% (8/46) 19.2% (105/546) 11.2% (17/152) .06
Congestive heart failure 15.2% (7/46) 16.7% (91/545) 25.0% (38/152) .06
Atrial fibrillation 15.2% (7/46) 11.9% (65/546) 20.7% (31/150) .02 c
Cerebrovascular disease 13.0% (6/46) 14.0% (76/544) 19.1% (29/152) .28
Angina 6.5% (3/46) 11.2% (61/546) 9.3% (14/150) .64
Dialysis 2.2% (1/46) 4.6% (25/546) 7.3% (11/151) .34
Note: Categorical variables are listed as percent (n/N); continuous variables are listed as median (interquartile range).
Abbreviations: ANOVA, analysis of variance; COPD, chronic obstructive pulmonary disease; TAMI, tibiopedal arterial minimally invasive.
aOmnibus p-value derived from Fisher's exact test for categorical variables and Kruskal–Wallis ANOVA for continuous variables. Bonferroni post hoc tests
were performed among all pairwise comparisons for variables with omnibus p-value <.05.
bNo statistically significant difference among any pairwise comparison.
cStatistically significant difference between Femoral and Dual Access groups.
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101 were carried using the TAMI technique (retrograde tibial-pedal
access) exclusively. Table 1 shows the demographic data. Only the
index procedure data was analyzed, and no statistical difference was
found in the distribution of mean ages, patients gender, BMI, and
comorbidities between groups.
The dual access group included patients with a statistically signifi-
cant (p < .001) higher median Rutherford class (5 vs. 4) and a lower
median number of tibial runoff vessels (1 vs. 2), denoting the group
with the most severe and complex disease.
Median fluoroscopy time (14 min), procedure time (64 min), hos-
pital stay (0 days; 7.9% staying ≥2 days), and contrast volume (50 mL)
were statistically significantly the lowest in the TAMI access group
(p < .001) (Table 2).
Sheath size for vascular access was found to be significantly dif-
ferent across all three cohorts with a 4Fr sheath most commonly
being used for TAMI and dual access and a 5Fr sheath most com-
monly being used for femoral access. Ultrasound guidance use was
significantly higher in the TAMI (99.1%) and dual access (97.2%)
TABLE 2 Procedure and recovery data by access type
Characteristic
Access type Significancea
TAMI Femoral Dual access Omnibus Bonferroni
(101 procedures) (840 procedures) (254 procedures) p-value Post hoc
Total heparin dose, 1,000 IU 9.0 (7.0–10.0) 7.4 (6.0–10.0) 10.0 (8.0–12.0) <.001 b,c,d
Peak ACT, s 205 (183–239) 210 (188–242) 223 (202–246) <.001 b,d
Contrast volume, ml 50 (30–75) 160 (118–216) 160 (115–220) <.001 c,d
Fluoroscopy time, min 14 (10–22) 18 (13–28) 40 (28–55) <.001 b,c,d
Procedure time, min 64 (47–86) 74 (53–99) 124 (95–156) <.001 b,c,d
Hospital stay, d 0 (0–1) 1 (1–1) 1 (1–1) <.001 b,c,d
Hospital stay ≥2 d 7.9% (8/101) 13.1% (110/840) 16.9% (43/254) .07
Note: Variables are listed as median (interquartile range).
Abbreviations: ANOVA, analysis of variance; TAMI, tibiopedal arterial minimally invasive.
aOmnibus p-value derived from Kruskal–Wallis ANOVA. Bonferroni post hoc tests were performed among all pairwise comparisons for variables with
omnibus p-value <.05.
bStatistically significant difference between Femoral and Dual Access groups.
cStatistically significant difference between TAMI and Femoral groups.
dStatistically significant difference between TAMI and Dual Access groups.
TABLE 3 Vascular access data by access type
Characteristic
Access type Significancea
TAMI Femoral Dual access Omnibus Bonferroni
(107 access sites) (954 access sites) (538 access sites) p-value Post hoc
Sheath size <.001 b,c,d
4Fr 100% (106/106) 8.6% (81/941) 52.3% (274/524)
5Fr 0.0% (0/106) 81.3% (765/941) 42.0% (220/524)
6Fr 0.0% (0/106) 6.5% (61/941) 5.3% (28/524)
7Fr 0.0% (0/106) 3.6% (34/941) 0.4% (2/524)
Ultrasound guidance 99.1% (106/107) 87.7% (835/952) 97.2% (523/538) <.001 b,c
Access success 100% (107/107) 99.1% (943/952) 100% (538/538) .06
Access success on first attempt 77.6% (83/107) 84.4% (786/931) 76.8% (411/535) <.001 b
Time to access, s 42 (15–98) 40 (15–99) 51 (17–126) .01 b
Note: Variables are listed as median (interquartile range).
Abbreviations: ANOVA, analysis of variance; TAMI, tibiopedal arterial minimally invasive.
aOmnibus p-value derived from Kruskal–Wallis ANOVA. Bonferroni post hoc tests were performed among all pairwise comparisons for variables with
omnibus p-value <.05.
bStatistically significant difference between Femoral and Dual Access groups.
cStatistically significant difference between TAMI and Femoral groups.
dStatistically significant difference between TAMI and Dual Access groups.
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groups when compared to the femoral access group (87.7%, p < .001)
(Table 3).
Table 4 shows that there was a significant difference between
the three groups with regards to the location of the target lesions
treated during the procedures (p < .001). Above the knee lesions were
most commonly treated with femoral access, below the knee (BTK)
lesions were commonly treated with TAMI access, and multilevel tar-
get lesions were routinely treated using dual access (femoral and tib-
ial). Accordingly, significant differences were observed between the
TAMI versus the femoral and dual access groups regarding the use of
treatment modalities such as orbital atherectomy and stent
placement. Orbital atherectomy was used more often with TAMI
access (reflecting the predominant treatment of BTK lesions;
p < .001), and stent placement was more commonly used in the com-
mon femoral access group (reflecting predominant treatment of sup-
ragenicular lesions; p < .001). The use of directional atherectomy was
significantly different between femoral (10.7%), dual access (5.1%),
and TAMI (1.0%) groups (p < .001). The use of chronic total occlusion
(CTO) and reentry devices showed a statistically significant difference
between the femoral and dual access groups (p < .001).
54.5% of the TAMI access procedures, were reinterventions. This
was statistically significant when compared to the femoral group (35%;
TABLE 4 Lesion data by access type
Characteristic
Access type Significancea
TAMI Femoral Dual access Omnibus Bonferroni
(101 procedures) (840 procedures) (254 procedures) p-value Post hoc
Lesion location <.001 b,c,d
Above knee 31.7% (32/101) 63.7% (535/840) 22.8% (58/254)
Below knee 51.5% (52/101) 23.1% (194/840) 46.1% (117/254)
Multilevel 16.8% (17/101) 13.2% (111/840) 31.1% (79/254)
Treatments
PTA 94.1% (95/101) 93.7% (787/840) 94.9% (241/254) .80
Orbital atherectomy 57.4% (58/101) 29.4% (247/840) 29.9% (76/254) <.001 c,d
Stent placement 15.8% (16/101) 35.2% (296/840) 33.1% (84/254) <.001 c,d
CTO device 11.9% (12/101) 7.9% (66/840) 18.5% (47/254) <.001 b
Laser atherectomy 6.9% (7/101) 6.8% (57/840) 11.4% (29/254) .06
Directional atherectomy 1.0% (1/101) 10.7% (90/840) 5.1% (13/254) <.001 bc
Thrombectomy 0.0% (0/101) 4.8% (40/840) 4.3% (11/254) <.05 c
Rotational atherectomy 0.0% (0/101) 3.8% (32/840) 3.5% (9/254) .10
Reentry device 0.0% (0/101) 1.9% (16/840) 7.1% (18/254) <.001 bd
Staged procedure 50.5% (51/101) 35.4% (297/840) 45.7% (116/254) <.001 b,c
Reintervention procedure 54.4% (55/101) 35.0% (294/840) 40.2% (102/254) <.001 c
Target vessel revascularization 37.6% (38/101) 34.8% (292/838) 35.8% (91/254) .83
Target lesion revascularization 34.7% (35/101) 32.9% (275/837) 33.5% (85/254) .92
Total treated length, mm 200 (80–300) 150 (60–300) 330 (250–500) <.001 b,d
Calcification 95.9% (94/98) 84.7% (637/752) 95.1% (231/243) <.001 b,c
In-stent restenosis 5.9% (6/101) 18.6% (155/834) 7.1% (18/254) <.001 b,c
Thrombus 0.0% (0/46) 4.3% (23/534) 2.7% (4/150) .06
Stenosis
Pretreatment, % 100 (90–100) 99 (90–100) 100 (100–100) <.001 b,c,d
Posttreatment, % 20 (10–28) 10 (0–20) 20 (10–20) <.001 b,c
Stenosis reduction, % 80 (70–90) 80 (70–90) 80 (70–90) .16
Treatment success (≤30% stenosis) 90.0% (90/100) 93.0% (734/789) 89.0% (219/246) .10
Note: Categorical variables are listed as percent (n/N). Continuous variables are listed as median (interquartile range): A (B–C).
Abbreviations: ANOVA, analysis of variance; TAMI, tibiopedal arterial minimally invasive.
aOmnibus p-value derived from Fisher's exact test for categorical variables and Kruskal–Wallis ANOVA for continuous variables. Bonferroni post hoc tests
were performed among all pairwise comparisons for variables with omnibus p-value <.05.
bStatistically significant difference between Femoral and Dual Access groups.
cStatistically significant difference between TAMI and Femoral groups.
dStatistically significant difference between TAMI and Dual Access groups.
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p < .001). The median total treated lesion length was highest for the
dual access cohort (330 mm) followed by the TAMI cohort (200 mm).
Calcification was similar between the TAMI and dual access groups
(95.9% and 95.1% respectively), however both were statistically more
prevalent than the 84.7% reported for the femoral group (p < .001).
Pretreatment stenosis was statistically different between all three
groups, with the dual access group encompassing CTOs exclusively
(p < .001). Posttreatment stenosis was also significantly different
between the groups, with the best results achieved in the femoral
when compared to both the dual and the TAMI groups (p < .001 for
each comparison). Treatment success was similar across all groups
(Table 4). The analysis of intraprocedural complications revealed that
perforations were more significant in the dual access group compared
to both the TAMI and common femoral groups (p < .001). The TAMI
TABLE 5 Complications by access type
Characteristic
Access type Significancea
TAMI Femoral Dual access Omnibus Bonferroni
(101 procedures) (840 procedures) (254 procedures) p-value Post hoc
Treatment success and complication-free 69.3% (70/101) 64.3% (540/840) 55.5% (141/254) .02 b,c
Any complication 22.8% (23/101) 26.8% (225/840) 33.9% (86/254) <.05 d
AV fistula 1.0% (1/101) 1.2% (10/840) 1.2% (3/253) >.99
At access site 0 0 0
Thrombus 0.0% (0/101) 1.3% (11/840) 1.6% (4/254) .63
At access site 0 0 0
Aneurysm 0.0% (0/101) 0.0% (0/840) 0.4% (1/254) .30
At access site 0 0 0
Pseudoaneurysm 1.0% (1/101) 1.0% (8/840) 2.8% (7/1254) .10
At access site 0 6 7
Hematoma 2.0% (2/101) 4.9% (41/840) 5.9% (15/254) .32
At access site 2 40 14
Infection 0.0% (0/101) 0.0% (0/837) 0.0% (0/253) >.99
Retroperitoneal bleed 0.0% (0/101) 0.4% (3/835) 0.0% (0/254) >.99
Compartment syndrome 0.0% (0/101) 0.0% (0/838) 0.0% (0/254) >.99
Transfusion 0.0% (0/101) 2.0% (17/837) 2.8% (7/254) .25
Amputation 1.0% (1/101) 0.5% (4/838) 1.2% (3/254) .26
Embolization 0.0% (0/101) 1.5% (13/839) 1.2% (3/254) .71
At access site 0 0 0
Dissection 15.8% (16/101) 16.8% (141/839) 15.4% (39/254) .87
At access site 0 0 1
Flow-limiting 1.0% (1/101) 3.7% (31/839) 5.1% (13/254) .17
Perforation 1.0% (1/101) 2.1% (18/839) 7.9% (20/254) <.001 b,c
At access site 0 0 0
Mild 0 12 10
Moderate 0 1 6
Severe 1 5 4
Rupture 0.0% (0/101) 0.2% (2/839) 0.0% (0/254) >.99
At access site 0 1 0
Spasm 1.0% (1/101) 1.2% (10/838) 1.6% (4/254) .91
At access site 0 1 0
Note: Variables are listed as percent (n/N) or counts.
Abbreviation: TAMI, tibiopedal arterial minimally invasive.
aOmnibus p-value derived from Fisher's exact test. Bonferroni post hoc tests were performed among all pairwise comparisons for variables with omnibus
p-value <.05.
bStatistically significant difference between Femoral and Dual Access groups.
cStatistically significant difference between TAMI and Dual Access groups.
dNo statistically significant difference among any pairwise comparison.
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and femoral access groups appeared to have overall, greater treat-
ment success with fewer complications compared to the dual access
group (p = .02) (Table 5).
4 | DISCUSSION
The TAMI technique was originally reported as a retrospective, small,
single-center series of patients in a prior publication, which
established the safety of the technique.5 The PRIME registry is the
first CLI registry in the United States with the sole focus on patients
with advanced PAD and CLI diagnoses. The registry examines all
aspects of CLI therapy from patient's clinical presentation to revascu-
larization modalities and ultimately clinical outcomes.7
CLI patients carry extremely poor outcomes and prognosis.8
Unfortunately, major amputation is still perceived as an acceptable
form of first line therapy, as shown in a recent study where almost
50% of patients did not undergo a vascular evaluation prior to
amputation.9
Patients undergoing a major amputation have a 10–12% 30-day
morbidity / mortality.10 A significant number never become ambula-
tory, risk contralateral amputation and suffer a higher mortality
rate.11,12 A recent NIS (Nationwide Inpatient Sample) study, showed
an increased rate of endovascular revascularization coupled with a
decrease in surgical revascularization, resulting in a decrease of in-
hospital mortality and major amputation rates in the United States,5
supporting that vascular amputations should not occur without
attempting revascularization.
A recent study of 72 thousand Medicare CLI patients, analyzed
outcomes of revascularization (surgical and endovascular) vs major
amputation, showing that revascularization was more cost effective
and produced better outcomes. Survival rates were significantly better
in the revascularization arm (38% endovascular and 40% surgical)
vs. the amputation arm (23%, p < .001).13 Patients with advanced
PAD and CLI have complex vascular anatomies and comorbidities
which can limit successful revascularizations. In an attempt to over-
come these hurdles, the TAMI strategy was proposed,6 however not
validated until now.
In this study, some of our results could be explained by the
fact that patients in the femoral access group had the least com-
plex lesions (shortest and least calcified). At the same time, our
findings are in agreement with a recent study that looked at CTO
lesions and their cap morphology, and showed that severe calcifi-
cation, cap morphology and lesion length were among the stron-
gest predictors that determined that a retrograde access (used
alone [29.6%] or in combination as dual access [50.6%]), would be
of benefit in 80.2% of the lesions and more likely to be successful
than a conventional, single access with antegrade approach to
treat the lesion.14 In our study, the dual access group encompassed
the most challenging lesions, as all were long (average treated
lesion length was 330 mm) and severely calcified CTOs. Given the
retrospective nature of this analysis, we are unable to comment
about how the access strategy was selected. However, combining
this data with that generated from the CTOP classification,14 it
appears safe to state that regardless of the location (supra or
infragenicular) of the lesion, long and calcified CTOs (>10 cm in
length), would benefit from a dual access strategy. If both the
proximal and the distal caps have an antegrade concave morphol-
ogy and the lesion is <10 cm in length, the traditional single access
with antegrade approach should suffice. If both caps have a retro-
grade concavity, and the lesion is <10 cm in length, then a straight
TAMI approach should be considered.
With regards to the treatment strategy, it appeared to preferen-
tially include orbital and laser atherectomy in the TAMI group. The bail
out stenting rate within the TAMI group remained low (15.8%). The
authors believe that the use of atherectomy in these complex and cal-
cific peripheral lesions decreased the rate of bail out stenting, which
remains in line with studies examining the use of atherectomy and the
limitations of plain balloon angioplasty (especially in infrapopliteal
arteries).15,16
The overall rate of complications remained low, rendering these
procedures and approaches safe. The highest complication rate
(despite the overall low number) was seen in the dual access group
(as a consequence of femoral access issues). The TAMI group had the
lowest complication rates. It also recorded the shortest procedure
times, with the lowest radiation exposure (fluoroscopy and cine time),
the shortest length of stay, and the lowest amount of contrast used.
This is to the best of our knowledge, the first time that all these strat-
egies are compared in the setting of a multicenter study of patients
with complex PAD and CLI.
5 | STUDY LIMITATIONS
Our study represents a retrospective analysis of prospectively col-
lected data and therefore carries the inherent limitation of such
design. There were no predetermined selection criteria to include the
patients in either group, which along with the high skill set of the
operators performing these procedures, could be viewed as potential
selection bias. The operators also had intrinsic knowledge of the data
from the CTOP classification,14 which may have influenced the access
selection strategy.
6 | CONCLUSION
This dataset supports the selection of patients with the aforemen-
tioned clinical syndromes and untreated infrapopliteal disease to be
approached via a retrograde tibiopedal access as part of a dual access
strategy or exclusively via TAMI technique.
TAMI has been shown to be safe (for both patients and operators:
lowest complication rate, lowest contrast volume used, lowest radia-
tion exposure), and efficacious (best treatment success rate, shortest
length of stay), in the setting of a large multicenter study. Larger pro-
spective and randomized studies may be useful to further validate this
approach.
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